Global clinical-stage biotechnology firm Ascentage Pharma has formed a strategic clinical collaboration with AstraZeneca’s hematology research and development centre Acerta Pharma.
AstraZeneca’s Calquence has been battling it out in mantle cell lymphoma since it won its first approval back in late 2017, but all along, the company has had its eye on another disease: chronic lymphocytic leukemia. And that’s where it’s scored its latest win.
Forty Seven Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.
Market Place
Share
Acerta Pharma News Full Screen View
Share
